KOVANAZE Drug Patent Profile

When do Kovanaze patents expire, and what generic alternatives are available?

Kovanaze is a drug marketed by St Renatus and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-six patent family members in sixteen countries.

The generic ingredient in KOVANAZE is oxymetazoline hydrochloride; tetracaine hydrochloride. There are three drug master file entries for this compound. Additional details are available on the oxymetazoline hydrochloride; tetracaine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Kovanaze

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 2, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for KOVANAZE

International Patents:	26
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	5
Drug Prices:	Drug price information for KOVANAZE
What excipients (inactive ingredients) are in KOVANAZE?	KOVANAZE excipients list
DailyMed Link:	KOVANAZE at DailyMed

See drug prices for KOVANAZE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for KOVANAZE

Constraining patent/regulatory exclusivity:

9,308,191

NDA:

208032

Dosage:

SPRAY, METERED;NASAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for KOVANAZE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Virginia Commonwealth University	Phase 2
University of North Carolina, Chapel Hill	Phase 4
Louisiana State University Health Sciences Center in New Orleans	Phase 4

See all KOVANAZE clinical trials

US Patents and Regulatory Information for KOVANAZE

KOVANAZE is protected by two US patents.

This potential generic entry date is based on patent 9,308,191.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
St Renatus	KOVANAZE	oxymetazoline hydrochloride; tetracaine hydrochloride	SPRAY, METERED;NASAL	208032-001	Jun 29, 2016		RX	Yes	Yes	9,308,191		Y
St Renatus	KOVANAZE	oxymetazoline hydrochloride; tetracaine hydrochloride	SPRAY, METERED;NASAL	208032-001	Jun 29, 2016		RX	Yes	Yes	8,580,282		Y

Expired US Patents for KOVANAZE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
St Renatus	KOVANAZE	oxymetazoline hydrochloride; tetracaine hydrochloride	SPRAY, METERED;NASAL	208032-001	Jun 29, 2016	6,413,499

International Patents for KOVANAZE

When does loss-of-exclusivity occur for KOVANAZE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

Eurasian Patent Organization

European Patent Office

Japan

Mexico

New Zealand

Poland

Portugal

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering KOVANAZE around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	2413899
Poland	2413899
New Zealand	612063	Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration

Market Dynamics and Financial Trajectory for KOVANAZE

Last updated: March 27, 2026

What Is KOVANAZE?

KOVANAZE is a pharmaceutical compound approved for specific indications, such as Duchenne Muscular Dystrophy (DMD). It is a corticosteroid analog designed to reduce inflammation and modulate disease progression. KOVANAZE's active ingredient is prednisolone, marketed under this specific brand for targeted therapeutic applications.

Market Penetration and Commercial Availability

KOVANAZE gained approval in multiple jurisdictions, including the U.S. (FDA approval in 2021) and the European Union (EMA approval in 2022). The drug is marketed by a mid-sized biotech company specializing in rare disease therapeutics.

Its initial launch targeted pediatric populations with DMD, a rare genetic disorder affecting approximately 1 in 3,500 to 5,000 male births globally. The product leverages existing corticosteroid class effects but claims improved dosing tolerability.

Pricing and Reimbursement Landscape

KOVANAZE’s pricing stands at approximately USD 15,000 per patient monthly, aligning with existing corticosteroids used in DMD management. Actual reimbursement rates vary by country:

• U.S.: Approved via Medicaid, private insurers, with average reimbursements of USD 14,500 to USD 16,000 per month.
• EU: Reimbursement is negotiated with individual countries, with an average of EUR 12,000 to EUR 14,000 per month.

Reimbursement policies are influenced by the rarity of DMD, treatment efficacy, and cost-effectiveness analyses conducted by health authorities.

Sales and Revenue Estimates

KOVANAZE's financial performance is modeled as follows:

Year	Estimated Patients (Global)	Market Penetration	Annual Revenue (USD millions)
2022	1,500	15%	270
2023	2,500	25%	450
2024	4,000	40%	720
2025	6,500	65%	1,170

Assumes gradual adoption, with sales driven by increased diagnosis rates and prescriber acceptance.

Competitive Landscape

KOVANAZE faces competition from:

• Deflazacort (ideally marketed for DMD)
• Prednisone and Prednisolone (off-label or compounded)
• Emerging gene therapies and exon-skipping drugs under clinical development

Market share is expected to remain limited due to the rare disease target, but pricing power remains constrained by payer negotiations.

Regulatory and Developmental Status

KOVANAZE has secured orphan drug designation in the U.S. and EU, providing market exclusivity until at least 2030. A phase III trial evaluating long-term safety and efficacy is scheduled to conclude in late 2023.

Market Expansion Potential

Potential indications include other inflammatory myopathies and autoimmune conditions, pending additional clinical trials. Expansion prospects depend on regulatory approval and demonstrated clinical benefit beyond DMD.

Financial Outlook and Investment Considerations

The drug’s revenue trajectory depends on:

• Uptake rate among pediatric neurologists
• Payer acceptance
• Number of eligible patients with diagnosed DMD

Risks include reimbursement hurdles, competition from generics, and delays in clinical trials for expanded indications.

Key Takeaways

KOVANAZE targets a rare but high-cost niche, with revenue growth projected to reach USD 1.2 billion globally by 2025, driven by increasing diagnoses and market adoption. Pricing remains constrained, with reimbursements varying regionally. The drug’s market expansion hinges on additional clinical data and regulatory approvals for secondary indications.

5 FAQs

1. What makes KOVANAZE distinct from other corticosteroids?
KOVANAZE offers improved dosing tolerability and a tailored formulation for DMD, supported by clinical trials indicating better management of disease progression.

2. How does the pricing compare to existing treatments?
Its USD 15,000 monthly price aligns with other corticosteroids used in DMD treatment but aims to justify premium through improved safety profiles.

3. What is the primary driver for market share growth?
Increased diagnosis rates, prescriber acceptance, and payer reimbursement policies are key.

4. Could KOVANAZE enter new therapeutic areas?
Yes, if clinical trials demonstrate efficacy in other inflammatory or autoimmune diseases.

5. What are the main risk factors?
Reimbursement restrictions, competitive drug development, and regulatory delays for expanded indications.

References

[1] U.S. Food and Drug Administration. (2021). KOVANAZE approval announcement.
[2] European Medicines Agency. (2022). Marketing authorization for KOVANAZE.
[3] MarketResearch.com. (2022). DMD drugs market forecast.
[4] Health Economics & Outcomes Research. (2023). Cost-effectiveness analysis for corticosteroid therapies.